Calithera Drops Development Of Lead Candidate Telaglenastat
Interim Phase II Lung Cancer Data Underwhelming
Executive Summary
Calithera’s most advanced oncological asset, telaglenastat, has failed in yet another indication, prompting the company to fall back on candidates in-licensed from Takeda just last month.
You may also be interested in...
Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
Engitix Collaborates With Dompé On Fibrosis And Cancer As It Eyes The Clinic
The UK biotech has struck up an unusual deal with its new investor that lets it retain control over its assets, as it raises $54m in a series A.
‘Bugs As Drugs’ Approach To Cancer Nears Advanced Development
Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.